Drugs / Sleeping Beauty Transposed PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04102436 | Mar 2024 | breast cancer, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sleeping Beauty Transposed PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04102436 ↗ |
| Action | Deplete | “The neoantigen TCR gene- modified cells can recognize and destroy the autologous cancer in vitro.” NCT04102436 ↗ |
| Modality | Cell therapy | “adoptive transfer of autologous PBL transposed with genes encoding TCRs” NCT04102436 ↗ |
| Route | Intravenous | “infused at a dose not to exceed 1.5e11 in 400 mL intravenously” NCT04102436 ↗ |